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Abstract
Background: Stat5 is a latent transcription factor that regulates essential growth and survival
functions in normal cells. Constitutive activity of Stat5 and the involvement of its C-terminally
truncated variant have been implicated in blood cell malignancies and mammary or breast cancer.
To distinguish the individual contributions of the Stat5 variants to mammary tumorigenesis, global
gene-expression profiling was performed on transgenic STAT5-induced tumors.
Results: We identified 364 genes exhibiting differential expression in mammary tumors developed
in transgenic mice expressing constitutively active STAT5 (STAT5ca) vs. its C-terminally truncated
variant (STAT5Δ750). These genes mediate established Stat5 effects on cellular processes such as
proliferation and cell death, as well as yet-unrelated homeostatic features, e.g. carbohydrate
metabolism. A set of 14 genes linked STAT5Δ750 expression to the poorly differentiated
carcinoma phenotype and STAT5ca to the highly differentiated papillary adenocarcinoma.
Specifically affected genes exhibited differential expression in an individual tumor set vs. its
counterpart and the intact mammary gland: 50 genes were specifically affected by STAT5ca, and
94% of these were downregulated, the latter involved in suppression of tumor suppressors and
proliferation antagonistics. This substantial downregulation distinguishes the STAT5ca-induced
tumorigenic consequences from the relatively equal effect of the STAT5Δ750 on gene expression,
which included significant elevation in the expression of oncogenes and growth mediators.
STAT5Δ750 mRNA expression was below detection levels in the tumors and the amount of
STAT5ca transcript was not correlated with the expression of its specifically affected genes.
Interestingly, we identified several groups of three to eight genes affected by a particular STAT5
variant with significant correlated expression at distinct locations in the clustergram.
Conclusion:  The different gene-expression profiles in mammary tumors caused by the
STAT5Δ750 and STAT5ca variants, corroborated by the absence of a direct link to transgenic
STAT5 expression, imply distinct metabolic consequences for their oncogenic role which probably
initiate early in tumor development. Tumorigenesis may involve induction of growth factor and
oncogenes by STAT5Δ750 or suppression of tumor suppressors and growth antagonists by
STAT5ca. The list of genes specifically affected by the STAT5 variants may provide a basis for the
development of a marker set for their distinct oncogenic role.
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Background
Stat5 is a latent transcription factor that is activated upon
binding of specific cytokines to their cognate membranal
receptors. Activation of Stat5 involves phosphorylation of
specific tyrosine residues by Janus kinase 2 (Jak2), and the
translocation of dimerized Stat5 molecules into the
nucleus to bind target sites (TTCC(A>T)GGAA) in individ-
ual gene promoters. Consequently, induction of a wide
variety of signaling events ensues, observed mainly in the
hematopoietic system and mammary gland. Stat5's trans-
activation domain (TAD) has been mapped to amino
acids 750 to 772 in the C-terminal domain of the mole-
cule [1]. This domain interacts with co-factors and is
essential for transcription activation [2]. The TAD encom-
passes the main diversity between STAT5a, which is prev-
alent in the mammary gland, and Stat5b which is more
abundant in the liver. Several naturally occurring C-termi-
nally truncated variants of Stat5 have been identified.
These variants are generated by alternative splicing or pro-
teolytic cleavage, most commonly by nuclear serine pro-
teases [3-5].
In the blood, naive T cells in the peripheral blood mono-
nuclear cell fraction exclusively express the C-terminally
truncated Stat5 [6]. Upon activation by mitogenic stimuli,
the truncated Stat5a and Stat5b are replaced by the full-
length Stat5, implying that the truncated proteins have
distinct functions. Naturally truncated forms of Stat5 have
been implicated in blood-cell cancer: 94% of patients
with relapsed leukemia expressed this Stat5 variant, sug-
gesting that it controls progression of the disease [7]. Con-
stitutive activation of Stat5 has also been linked to a
variety of blood-derived malignancies such as BCR-ABL-
induced chronic myeloid leukemia (CML [8]), acute mye-
loid leukemia (AML) and acute lymphoid leukemia (ALL
[9]).
In the mammary gland, Stat5's expression and activity are
induced during pregnancy and lactation and decrease
upon involution. During these stages, Stat5 controls epi-
thelial cell proliferation, final differentiation, lactogene-
sis, cell survival and tissue remodeling. These cellular
processes play a major role in the structural and func-
tional adaptation of the gland to the specific stages of the
female reproductive cycle (reviewed in [10]). Overexpres-
sion of STAT5 in transgenic mice induced proliferation of
mammary epithelial cells during pregnancy, increased β-
casein synthesis upon lactation, and delayed involution
[11]. In contrast, the C-terminally truncated variant was
unable to induce β-casein/luciferase activity upon prolac-
tin stimulation in vitro. Its expression in the mammary
glands of transgenic animals resulted in reduced rates of
cell proliferation at pregnancy and increased apoptosis
during involution. Morphological signs of milk secretion
upon parturition were delayed [12].
Stat5 has also been associated with breast cancer. Stat5a
nuclear localization was observed in 76% of breast cancer
specimens and a positive correlation was established
between its nuclear localization and the level of histolog-
ical differentiation of the tumors [13]. Inactivation of
Stat5a in transgenic mice expressing transforming growth
factor (TGF) α or the SV40 T antigen delayed hyperplasia
[14] and mammary cancer progression. More recently, a
direct effect for Stat5 on mammary tumorigenesis was
established [15,16]. Overexpression and forced activation
of STAT5 caused parity-dependent development, most fre-
quently of differentiated tumors, in transgenic post-estro-
pausal female mice. Surprisingly, comparable rates of
tumors (~8%) with similar latency periods were moni-
tored in mice expressing the C-terminally truncated STAT5
protein, though the amount of poorly differentiated
tumors in these mice was higher.
Both the constitutively active and C-terminally truncated
variants of Stat5 are potent oncogenes. In this study, we
sought to determine the distinctness of their effects and
the exclusive contribution of each variant to the onco-
genic profiles of gene expression.
Profiling global gene expression in breast cancer has
improved our understanding of the clinical diversity of
this disease, allowing a better classification of its subtypes
and definition of their response to drug treatment.
Attempts to predict survival rates have also been reported
[17-20]. Transgenic mouse models have been used to
study the signatures of specific genes involved in initia-
tion and maintenance of the disease. Genetic analysis of
these mouse models could be highly relevant to human
cancer [21-23]. The data also suggest that genes involved
in the same pathway generate tumors with similar expres-
sion profiles, which are distinct from the profiles of
tumors arising from other transgenic pathways [24].
Gene-expression profiles were compared in tumors
caused by the constitutively active STAT5 (STAT5ca) and
its C-terminally truncated variant (STAT5Δ750). A set of
364 differentially expressed genes was identified. Analysis
and classification of these genes suggest that defined dif-
ferences, possibly triggered at early stages of tumor devel-
opment, characterize these Stat5 variants.
Methods
Mouse mammary-tumor samples
Mammary tumors were derived from transgenic mice car-
rying one of two Stat5 variants on a FVB/N background:
(i) constitutively activated STAT5, termed STAT5ca, com-
prising sequences from three genes: amino acids 1–750
from ovine Stat5, which is homologous to mouse Stat5a,
677–847 from human Stat6, and 757–1129 from mouse
Jak2 and (ii) a deleted construct, STAT5Δ750, prepared byBMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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introducing a stop codon at the respective site of the
native Stat5 DNA sequence, thus eliminating the expres-
sion of its TAD. These constructs were inserted into the β-
lactoglobulin (BLG) multiple-cloning site for mammary-
gland-specific expression [11]. Upon identification,
tumors were excised and snap-frozen for RNA isolation
and validation studies. The pathological analysis of the
tumors was performed by Dr. Robert Cardiff (University
of California, Davis) as previously described [15]. All ani-
mals used in this study were treated humanely. Study pro-
tocols were in compliance with the regulations of the
Israeli Ministry of Health and local institutional policies
(approval no. IL- 39-03).
RNA extraction and microarray hybridization
The protocols for RNA extraction from tumors and mam-
mary glands and microarray hybridization were as previ-
ously described [23]. Briefly, RNA was extracted from
individual tumors or mammary glands with TRIZOL and
reverse-transcribed. Equal amounts of complementary (c)
RNA from each tumor were hybridized to an Affymetrix
GeneChip® Mouse Genome 430A 2.0 array (Affymetrix,
Santa Clara, CA), which includes approximately 14,000
annotated genes from the mouse genome. Hybridization
and signal quantitation were performed according to
Affymetrix's protocol by the Biological Services of the
Weizmann Institute of Science (Rehovot, Israel). Total
RNA (15 μg) was reversed-transcribed using a T7-
oligo(dT) promoter-primer in the first-strand DNA-syn-
thesis reaction. Following RNase H-mediated second-
strand cDNA synthesis, the double-stranded cDNA was
purified and used as a template for the subsequent in-vitro
transcription reaction. This reaction was carried out in the
presence of T7-RNA polymerase and a biotinylated nucle-
otide analogue/ribonucleotide mix for cRNA amplifica-
tion and biotin labeling. The biotinylated cRNA targets
were then cleaned up, fragmented, and hybridized to the
GeneChip expression array. The chip was reacted with
streptavidin-phycoerythrin and then with biotinylated
anti-streptavidin antibody (Vector Laboratories, Burlin-
game, CA). Arrays were scanned by GeneArray scanner
G2500A (Hewlett Packard, Palo Alto, CA), visually
inspected for hybridization imperfections and analyzed
using Affymetrix Microarray Suite software version 5.0 by
scaling to an average intensity of 250. The raw data have
been deposited in the public repository "Gene Expression
Omnibus" (GEO), accession no. GSE15119.
Statistical, hierarchical clustering and functional 
annotation analyses
The data were analyzed with GeneSpring (Silicon Genet-
ics, Redwood City, CA) using the MAS5 algorithm [25].
Gene-expression data were normalized "per chip" and
"per gene". For "per chip" normalization, all expression
data on a chip were normalized to the 50th percentile of
the measurements taken from all values on that chip. For
"per gene" normalization, each gene's measurement in
the selected samples was divided by the median of the
gene's measurements in the respective control group,
according to the type of comparison being made. When
profiles were compared between tumors induced by each
of the two transgenic Stat5 variants, the expression of a
given gene was normalized to the median of the expres-
sion level in the wild-type mammary gland samples. This
allowed relating the level of expression of a given gene to
that in the mammary gland [23]. When the analysis also
included values obtained from the mammary glands, the
expression of a given gene was normalized to the median
of the expression levels of all genes from all samples. The
normalized data were log-transformed and the differences
in gene expression (based on the individual values
obtained from each tumor) were calculated using one-
way statistical analysis of variance (ANOVA). The statisti-
cal analysis, which discriminates between the effects of
transgenic STAT5 variants, was cross-validated by the K-
nearest-neighbor algorithm using the leave-one-out meth-
odology [26]. The differences in gene expression between
the tumors and the mammary gland were determined by
post-hoc Student-Newman- Keuls analysis. Note that the
different expression patterns of selected genes in the array
had been previously confirmed by semi-quantitative PCR
analyses of selected genes, and hybridization to the
respective probes [23].
Genes exhibiting a significant (P ≤ 0.05) twofold differ-
ence in expression between transgenic variants were cate-
gorized into "biological functions and/or diseases" using
Ingenuity Pathways Analysis (IPA) software (Ingenuity
Systems, Mountain View, CA). The probability of each
term being identified by random chance was calculated
using Fisher's exact test http://www.ingenuity.com/.
Unsupervised hierarchical clustering (GeneSpring) organ-
ized these genes according to their similarity or dissimilar-
ity in expression profiles, placing the cases with similar
expression profiles together as neighboring rows in the
clustergram.
Multivariate correlations were determined between the
expressions of transgenic STAT5 and specifically affected
genes, and among the expressions of the affected genes in
the individual tumors using JMP statistical software (Ver-
sion 7.0, SAS Institute, Inc., Cary, NC).
Real-time PCR
Quantitative real-time PCR analyses were performed in an
ABI Prism 7700 (Applied Biosystems, Foster City, CA) in
a 20-μl reaction volume containing 4 μl cDNA (diluted
1:100), 10 μl SYBR Green PCR Master Mix (Applied Bio-
systems) and 10 μM primers. The thermal-cycle condi-
tions consisted of 2 min at 50°C, 2 min at 95°C, and 40BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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cycles of 15 s at 95°C and 1 min at 60°C. The primers
were designed so that the PCR would yield a single prod-
uct without any primer dimerization, and the product was
verified using a dissociation protocol [see Additional file
1, data sheet A]. The primers were designed across exon-
exon junctions to ensure that there was no genomic DNA
contamination in the cDNA samples. The amplification
curves for the selected genes (70–100 bp) were parallel.
Results
Establishment of distinct expression profiles for the effects 
of STAT5ca and STAT5 750 in mammary tumors
RNA was independently extracted from six tumors devel-
oped in mice carrying the BLG/STAT5Δ750 transgene and
from seven tumors originating in mice carrying BLG/
STAT5ca. Tumor phenotypes were either poorly differen-
tiated carcinoma or papillary adenocarcinoma (Fig. 1 and
described in [15]). Following microarry hybridization, we
identified a set of 381 features (364 genes) exhibiting a
significant (P < 0.05) twofold difference in expression
level between tumors originated from mice carrying the
two transgenic STAT5 variants [see Additional file 1, data
sheet B]. Their grouping according to type of transgenic
STAT5 variant was confirmed by principal component
analysis (PCA, [27]) and unsupervised hierarchical clus-
tering (Fig. 1).
IPA software was used to annotate the differentially
expressed genes into processes involved in cellular metab-
olism and cancer (Table 1). In both categories, the highest
number of differentially expressed genes in the STAT5ca-
vs. STAT5Δ750-induced tumors was associated with two
opposing processes: cell proliferation and cell death [see
Additional file 1, data sheet C]. The involvement of some
of the genes affecting cancer cell death–Adm, Cflar, Cyr61,
Ddit4, Itgb1, Mapk1, Mapk8, Tgfβ2, Tpm1, Vegfα and
Wasf1, was demonstrated in breast cancer cell lines [see
Additional file 1, data sheet C]. The activities of Itgb1
(coding for integrin β1), TGFβ2 and Vegfα are mediated,
at least in part, by Cyr61 (CCN1, [28-30])–a secreted
matrix protein involved in the clinical progression of
breast cancer to an invasive phenotype [31].
Cyr61 can be also found among the differentially
expressed genes regulating the formation of cellular pro-
trusions and filopodia–cellular extensions needed for cel-
lular interactions and movement [32]. Most of the listed
genes affecting this process, including the laminin α5
(Lama5) [33] and the VEGF receptor PVR [34], were
expressed at higher levels in the STAT5Δ750-induced
tumors. This suggests higher involvement of this variant
in cell movement and tumor extension. The GDP/GTP
exchange protein Fabrin 4 (FDG4, [34] and the ganglio-
side GD3-synthase (ST8SIA)1 which marks ER-negative
breast cancer tumors [35] were the only genes in this con-
text that were expressed at a higher level in the STAT5ca-
induced tumors.
The differential expression of genes mediating carbohy-
drate metabolism indicates involvement of the STAT5 var-
iants in cellular homeostasis as well. Most of the genes
involved in the transport and utilization of carbohydrates
were more highly expressed in tumors caused by the BLG/
STAT5Δ750 transgene, for example, Aqp7 and Aqp9
which code for proteins operating as glycerol channels
[36], or glucokinase (Gck) which encodes a protein that
catalyzes the conversion of glucose to glucose-6-phos-
phate, thus maintaining glucose homeostasis [32].
Hierarchical clustering of genes affected by transgenic 
STAT5 variants
Unsupervised hierarchical clustering assembled the genes
that were differentially expressed between the two sets of
STAT5-affected tumors into four clusters (Fig. 2 and [see
Additional file 1, data sheet D]). Cluster 1 contains genes
that were more highly expressed in the STAT5ca-induced
tumors than in their STAT5Δ750 counterparts, resulting
from downregulation of the STAT5Δ750-induced genes
compared to their expression in the mammary gland (rep-
resented by the value "1"). In contrast, genes allocated to
clusters 2, 3 and 4 were more highly expressed in the
STAT5Δ750-induced tumors. In cluster 2, the STAT5Δ750
affected genes were, in general, also more highly expressed
than in the wild-type gland. In cluster 3, the STAT5Δ750-
affected genes maintained mammary gland levels of
expression while their STAT5ca counterparts were
expressed at a lower level. Finally, in cluster 4, differential
expression relative to the mammary gland was noted:
higher expression of genes induced by the BLG/
STAT5Δ750 transgene, lower expression of genes affected
by its BLG/STAT5ca counterpart.
Annotation of the 76 genes in cluster 1 assembled them
into non-malignant cellular processes, including amino
acid modification, hematopoiesis and neurological disor-
ders [see Additional file 1, data sheet E]. In contrast, all
other clusters which included genes expressed at higher
levels in the STAT5Δ750-induced tumors contained the
"cancer" category which assembled genes into specific
tumorigenic processes. In this category, genes mediating
"invasion", such as Adm, Itg3 and Igf2, converged to clus-
ter 2. In contrast, most genes involved in tumor growth,
transformation and differentiation were expressed at
lower levels and were therefore allocated to cluster 3.
Transgenic STAT5 variants exert distinct effects on a 
limited set of specifically affected genes
Specifically affected genes differed in their expression
between an individual tumor set and its counterpart, and
between that set and the intact mammary gland. To iden-BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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Principal component analysis (PCA) and unsupervised hierarchical clustering into distinct tumor genotypes Figure 1
Principal component analysis (PCA) and unsupervised hierarchical clustering into distinct tumor genotypes. 
Mammary carcinomas and papillary adenocarcinomas were developed in transgenic mice expressing constitutively activated 
STAT5 (STAT5ca) or truncated STAT5 (STAT5Δ750). PCA (A) and unsupervised hierarchical clustering (standard correlation, 
B) were performed on genes that were expressed at significantly (P < 0.05; twofold) different levels in tumors induced by the 
two STAT5 variants. Both analyses confirmed their distinction based on the transgenic STAT5 variant carried by the host 
female.BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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Table 1: Cellular metabolism and cancer processes affected by genes that are differentially expressed in tumors caused by the different 
transgenic STAT5 variants.
Category Process Process Annotation Significance No. of Molecules
Carbohydrate Metabolism formation formation of inositol phosphate 1.53-2 3
production production of carbohydrate 8.32-3 7
transport transport of carbohydrate 1.66-5 11
utilization utilization of carbohydrate 1.04-2 3
Cardiovascular System Development and 
Function
angiogenesis angiogenesis of cells 1.69-3 5
cardiovascular process cardiovascular process of cornea 6.15-4 6
Cell cycle G1 phase G1 phase of eukaryotic cells 1.88-2 11
G2 phase G2 phase of tumor cell lines 1.59-2 5
interphase interphase of eukaryotic cells 1.36-2 17
length length of telomeres 1.72-2 3
mitogenesis mitogenesis 3.30-3 10
Cell death cell death cell death 1.43-3 74
cell death cell death of cell lines 5.03-4 49
cell death cell death of tumor cell lines 2.11-4 41
Cellular Assembly and Organization formation formation of cellular protrusions 1.18-2 7
formation of filopodia 7.48-4 8
formation of plasma membrane 
projections
1.77-3 13
growth growth of plasma membrane 
projections
1.21-2 13
Cellular Growth and Proliferation formation formation of eukaryotic cells 2.93-3 13
growth growth of cell lines 4.41-4 36
proliferation proliferation of eukaryotic cells 1.58-6 65
Cellular Movement cell movement cell movement of eukaryotic cells 1.25-3 45
cell movement of tumor cell lines 1.23-4 22
homing homing of eukaryotic cells 5.69-3 17
migration migration of tumor cell lines 2.23-4 17
DNA Replication, Recombination and 
Repair
synthesis synthesis of DNA 3.78-3 17
Hematological System Development and 
Function
hematological process hematological process 7.64-3 24
Nervous System Development and 
Function
growth growth of neurites 1.02-2 13
Tissue Morphology contraction contraction of tissue 6.01-4 12
Cancer benign tumor benign tumor 1.55-2 10
carcinoma in situ carcinoma in situ 1.77-2 6
apoptosis apoptosis of tumor cell lines 2.33-4 37
cell death cell death of tumor cell lines 2.11-4 41
cell death of breast cancer cell lines 1.12-2 11
cell movement cell movement of tumor cell lines 1.23-4 22
growth growth of tumor 2.03-3 10
growth of tumor cell lines 1.01-2 25
metastasis migration of tumor cell lines 2.23-4 17
proliferation proliferation of tumor cell lines 1.29-4 28
transformation transformation of cells 1.31-2 19BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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tify genes which were specifically affected by each of the
STAT5 variants, three mammary gland samples were
added to the analysis, and the level of expression of the
364 genes exhibiting differential expression among
STAT5-induced tumors was re-evaluated (Fig. 3). This
analysis identified 52 genes associated with the effect of
the STAT5Δ750 transgene [(STAT5Δ750  ≠ STAT5ca =
mammary gland (M.G.)], 50 genes that were specifically
affected by STAT5ca (STAT5ca ≠ STAT5Δ750 = M.G.), and
62 genes with differential expression in the three groups
(STAT5Δ750 ≠ STAT5ca ≠ M.G., and [see Additional file 1,
data sheet F]). Unexpectedly, 94% of the STAT5ca-affected
genes (47 genes) were downregulated compared to their
expression in the STAT5Δ750-induced tumors and the
wild-type mammary gland. A considerable number of
these genes could be associated with anti-proliferative or
tumor-suppressive processes, including apoptosis induc-
ers Edg3 and Jip-2 [37,38], differentiation inducers Msln,
Il5ra and Ebf2 [39-41], Prp19 (also known as Pso4) which
is involved in DNA repair [42], Ragef3 which blocks
chemotaxis induced by angiogenic factors [43] and Tyrp,
which is expressed in poorly metastatic breast cancer and
whose downregulation augments metastasis [44].
A more equal deviation characterized the STAT5Δ750-
affected genes. Only 38% of these genes were downregu-
lated, whereas the rest were expressed at significantly
higher levels compared to their expression in the
STAT5ca-induced tumors or the wild-type mammary
gland. In contrast to the STAT5ca-affected genes that were
located in cluster 3, their STAT5Δ750 counterparts spread
mainly among cluster 1 (20 genes, 38%) and cluster 2 (29
genes, 56%), with a residual presence in cluster 4 (3 genes,
6%). Upregulated and downregulated genes were anno-
tated with different activities (Table 2). Upregulated genes
affected angiogenesis, cell adhesion, cell-cell signaling,
and progression through the cell cycle. Downregulated
genes were involved in insulin receptor binding, DNA rep-
lication, chromatin remodeling and G-protein receptor
pathways.
The expression of STAT5ca in individual tumors does not 
correlate with the expression of its specifically affected 
genes
Does the deviation in gene expression between the two
sets of tumors result from an early transgenic STAT5 effect,
or does continuously deregulated STAT5 expression in the
tumors govern the gene-expression profile?
STAT5ca and STATΔ750 expression levels were analyzed
by real-time PCR in the respective tumors. In contrast to
measurable STAT5ca transcripts, STAT5Δ750 mRNA did
not reach detection levels. There was no significant corre-
lation between expression of STAT5ca in the tumors and
that of any of its affected genes [see additional file 2, bot-
tom row of upper section]. Interestingly, within the genes
affected specifically by STAT5ca, a few groups were identi-
fied which were linked by significant correlations between
the expressions of their individual members. The genes
with the highest number of internal correlations are pre-
sented [see Additional file 2]. The largest such group
included Mapk8 (top row), Wnt8b, Ptn, Pramel6, Klra5,
Edg3, Ebf2 and Tyrp1. Significant gene-expression correla-
tions were also detected among the STAT5Δ750-affected
tumors, the largest group including Wnt7b, Scgb1a1,
Itga3, Mrpplf4 and Cspg2. Analyses of these gene groups
by DAVID [45] and IPA software could not assemble the
individual members into a single metabolic pathway or
identify a mutual effector.
Distinct distribution into clusters was observed when the
specifically affected genes were allocated. With the list of
highly correlated genes as a core, the STAT5ca-affected
genes were assembled into a small region in the upper sec-
tion of cluster 3 (Fig. 2), confirming a lower level of
expression compared to both the STAT5Δ750-induced
tumors and the wild-type mammary gland. In contrast,
genes affected by STAT5Δ750 were distinctly located in
clusters 2 and 1. Their location in cluster 2 implied a
higher level of expression compared to those specifically
affected by the STAT5ca transgene or the wild-type mam-
mary gland. Their presence in cluster 1 as well reflected
the more even distribution between upregulated and
downregulated genes.
Reproducing transgenic STAT5 effects in a "test set" of 
tumors
Our next step was to confirm the "transgenic signature" of
the STAT5 variants in independent groups of tumors.
From the list of 50 genes specifically affected by STAT5ca,
six candidates were selected and their expression was ana-
lyzed by real-time-PCR in a separate set of tumors caused
by the two STAT5 variants. This "test set" included seven
tumors that had developed in BLG/STAT5ca-transgenic
mice (four papillary adenocarcinomas, one squamous
carcinoma and two poorly differentiated carcinomas) and
six tumors that had developed in the BLG/STAT5Δ750
mice (one papillary adenocarcinoma, three micropapil-
lary adenocarcinomas, one squamous carcinoma and one
adenosquamous carcinoma). As demonstrated in Table 3,
the differences between the expressions of genes affected
by STAT5Δ750 vs. STAT5ca detected in the original set of
tumors that was tested by the array analysis were compa-
rable to those found in the "test set" which was subjected
to real-time PCR.
Discussion
The constitutively active Stat5 and its C-terminally trun-
cated variant have been implicated in cancer in laboratory
animals and humans. Here we established a model sys-BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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Unsupervised hierarchical clustering of genes that are differentially expressed in tumors induced by STAT5ca and STAT5Δ750  transgenes Figure 2
Unsupervised hierarchical clustering of genes that are differentially expressed in tumors induced by STAT5ca 
and STAT5Δ750 transgenes. Genes with statistically significant (P < 0.05), over twofold differences in expression levels 
between the two sets of tumors were clustered. In each cluster, cellular processes were annotated. The normalized intensity 
values indicate relative expression levels compared to the median gene expression in the intact mammary gland ("1"). Arrows 
mark genes that are specifically affected by STAT5ca (gray) or STAT5Δ750 (black) and listed in Table 2.BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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Venn Diagrams of genes affected by the transgenic STAT5 variants relative to their expression in the mammary gland Figure 3
Venn Diagrams of genes affected by the transgenic STAT5 variants relative to their expression in the mam-
mary gland. A. Levels of expression in the two sets of tumors were compared. B. Mammary gland expression levels were 
included in the analysis to identify genes that differ in their expression in a particular group (specifically affected genes). C. Up- 
or downregulation of gene expression in individual groups was defined.BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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Table 2: Classification, annotation and expression levels of genes, specifically affected by the STAT5 variants. 
Specifically affected by BLG/STAT5ca
Ras small GTPase Rasd1, Rasd2
GTPase activity Rasd1 Rasd2 GNAO1
Rho GAPs Chn1
G-protein GNAO1
G-protein-coupled receptor Edg3, Adra2c
Cytoskeleton protein Tnni1, Cnn1, Rsnl2
GEFs Rapgef3
Cytoskeleton rearrangement Ptn, pip5k1b
Organization of microtubules Rsnl2
Cell-cell recognition/signaling/adhesion Msln, ptn, Rapgef3, Adra2c
Cell migration Edg3
Mammary development Ebf2, Gli2
Immune system/response Csf2ra, il5ra, Foxji, H2-K1, EDG3
Neurons Elavl3, Wnt8a, Gfra2, Phgdh
DNA damage response/cell cycle Prp19 (DDR), Magea2 (inhibits p53 activation)
Apoptosis inhibition Cflar
Tight junction Mpdz, Gja7
Potassium channel Kcne4
JNK signaling JIP-2, Rapgef3, Mapk8
Transcription factor Max
Defense response Klra5, Klra22
Ribosome Rps15a
Urea cycle Otc
Signal transduction Mapk1, JIP-2, Rapgef3, Mapk8, Gfra2, Adra2c, Rasd1, Rasd2, GNAO1, 
Chn1, EDG3, Wnt8a, JIP-2
Protein phosphates inhibitor activity PPP1R2P9
Regulation of nucleotide and nucleic acid metabolism Ddx3y
Bacterial cell wall degradation lysmd2
Regulating hemoglobin oxygen affinity Bpgm
Expressed in the early embryo Pramel6
Not associated Tyrp1, 1700065I17Rik, Serpinb6c, 2010003K11Rik, 4931412G03Rik 
(Trpd52l3)
Specifically affected by BLG/STAT5Δ750
Adm, Mrpplf4, Cyr61 Angiogenesis
Cspg2, Itgβ1, Itgβ3, Scgb1a1, Pcdhb5, Rin1, Lana5, Cyr61, Cav2 Cell adhesion
Itgβ1, Foxk1, Rnf134, Peg3, Mkrn3 Progression through cell cycle
Peg3, Kif5c, Pcdhb5, Ivns1abp, Mkrn3 Neuron
Foxk1, Rnf134, Peg3 Transcription factor activity
Gdi2, Rin1 GTPase activator activity
Tec, Trhr, Oprl, V1ra9, 5930418K15Rik G-protein-coupled receptor protein signaling pathway
Adm, Wnt7b, Pcdhb5 Cell-cell signaling
Irs4 Insulin receptor binding
Orc3l DNA replication
Eif2s2 Translation initiation factor activity
Cugbp1 Translation repressor activity
Cdv3, Cyr61 Cell proliferation
Hsd17b1 Estradiol 17-beta-dehydrogenase activity
H2-Eb1, Tec, Igbp1b, Nudcd1 Immune response
Nudcd1, Mkrn3, Msmb, Cav2, Gnmt, Cryl1 Cancer-related
Kif5c Microtubule-based movement
Abhd1 Hydrolase activity
Klf1 Chromatin remodeling
Peg3, Mkrn3 Apoptosis
B3galt1 Transferase activity, transferring glycosyl groups
Igbp1b B-cell activation
Krt2-17, Kif5c Cytoskeleton organization and biogenesis
Pdss1 Isoprenoid biosynthetic processBMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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tem, based on mice expressing the individual transgenic
STAT5 variants, to study the distinct variants' oncogenic
role in the mammary gland.
Stat5 mediates proliferation in the mammary gland of
pregnant females [46], and different effects of its two var-
iants have been demonstrated in transgenic mice during
the reproductive cycle: STAT5ca-induced proliferation
during pregnancy and delayed apoptosis and tissue
remodeling during involution [11]. The opposite has
been shown for the STAT5Δ750 variant [11,12]. This
diversity results from the structural differences between
the STAT5 variants which involves either forced activation
or lack of TAD-mediated interactions with the proteins,
such as CBP/p300, that recruit acetylases [47]. Both STAT5
variants seem to have a persistent effect, probably on
chromatin structure and accessibility [16,48,49], which
results in different profiles of gene expression in the devel-
oping tumors.
Differential expression of 364 genes was found between
mammary tumors developed in BLG/STAT5ca- and BLG/
STAT5Δ750-transgenic mice. These genes were involved in
a set of cellular activities, many of which could still be
associated with the two main processes mediated by Stat5
in the intact tissue: cell proliferation and cell death. The
individual genes that established the specific mark of the
STAT5 variants in the tumors were identified by gene-
array analysis and their differential expression in the pop-
ulation was confirmed in a distinct "test set" of tumors
using a different detection method, real-time PCR. Of spe-
cial interest was the gene encoding the proto-oncogene
Met, which was expressed in the STAT5Δ750-induced
tumors at a 22-fold higher level than in their STAT5ca-
induced counterparts. The product of Met is the hepato-
cyte growth factor receptor which encodes tyrosine-kinase
activity. The ligand-activated cytoplasmic domain of the c-
Met receptor induces growth motility, morphogenesis and
angiogenesis [50]. In breast cancer, c-Met overexpression
is associated with tumor progression (reviewed in [51])
and has an independent predictive value for poor survival,
even in early-stage patients with negative lymph nodes
[52]. Expression levels of Met were upregulated relative to
intact tissue in the STAT5Δ750-induced tumors and
downregulated in tumors developed in mice carrying the
BLG/STAT5ca transgene. This differential expression sug-
gests a more aggressive downstream cascade in the former.
Other genes with exceptionally high expression levels in
the STAT5Δ750-induced tumors, which were not affected
by the STAT5ca variant, were proliferin and Igf2. Proliferin
is a member of the prolactin family which is involved in
progenitor cell expansion along the luminal and myoepi-
thelial lineage [53] and Igf2 plays a pivotal role in fetal
and cancer development by signaling via the IGF-I and
insulin receptors, and activating the estrogen-signaling
cascade [54]. Unfortunately, studies on these genes [55-
57] do not include or base additional lists of genes with
altered expression profiles that might be compared to our
data and aid in delineating the pathway(s) involved in the
tumorigenic effect of STAT5Δ750.
Pi4k2b Phosphotransferase activity, alcohol group as acceptor
Nol5 Ribosome biogenesis and assembly
Fabp5 PPAR signaling pathway/lipid metabolic process
Gnmt Breaks down the protein building block (amino acid) methionine
4930422J18Rik(SSB-1) Ubiquitin cycle
C80171, 1810030O07Rik, Es2el, Pter Not associated
In black–genes with higher expression in tumors induced by STAT5Δ750. In gray–genes with higher expression in tumors induced by STAT5ca.
Table 2: Classification, annotation and expression levels of genes, specifically affected by the STAT5 variants.  (Continued)
Table 3: Validation of the differences in gene expression determined by the array analysis using real-time PCR of gene expression in a 
test set of tumors.
Gene Tumor set 1
(Microarray analysis, arbitrary units)
Tumor set 2 (test set)
(Real-Time PCR analysis, 2-Δct × 1,000)
BLG/STAT5Δ750 
tumors
BLG/STAT5ca 
tumors
Fold change (BLG/
STAT5Δ750/BLG/
STAT5ca)
BLG/STAT5Δ750 
tumors
BLG/STAT5ca 
tumors
Fold change (BLG/
STAT5Δ750/BLG/
STAT5ca)
Edg3 1.59 ± 0.21 0.43 ± 0.15 3.64 0.10 ± 0.02 0.04 ± 0.01 2.08
Mapk8 1.30 ± 0.19 0.51 ± 0.12 2.54 0.64 ± 0.189 0.43 ± .05 1.49
Wnt8a 1.41 ± 0.31 0.44 ± 0.14 3.15 1.41 ± 0.380 0.37 ± 0.21 3.75
Ptn 1.69 ± 0.48 0.46 ± 0.25 3.68 1.01 ± 0.219 0.48 ± 0.07 2.09
Foxk1 3.49 ± 0.97 0.86 ± 0.19 4.04 0.35 ± 0.118 0.25 ± 0.02 1.42
Tyrp1 1.37 ± 0.21 0.41 ± 0.17 3.33 2.22 ± 1.159 0.47 ± 0.18 4.71BMC Genomics 2009, 10:231 http://www.biomedcentral.com/1471-2164/10/231
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A group of genes regulating carbohydrate metabolism and
transport could also be discerned. These genes were not
associated with Stat5 effects in the intact mammary gland
but were differentially expressed in the two sets of tumors.
Their role in the tumors could be related to altered levels
of metabolism (i.e. higher metabolic rate in the
STAT5Δ750-induced tumors) rather than cancer growth
per se.
Expression of an additional set of 14 genes linked the
effects of the BLG/STAT5Δ750 and the BLG/STAT5ca
transgenes to the resulting phenotypes of poorly differen-
tiated carcinoma or highly differentiated papillary adeno-
carcinoma, respectively (r = 0.97) [see Additional file 1,
data sheet G and [16]]. These genes cover a wide variety of
cellular functions: calcium sensitivity of the myofibrils
(troponin I and tropomyosin 1), interaction between the
cell and the extracellular matrix (endomucin), normal
adipose tissue development (lipin 3), lipid metabolism,
cellular growth and apoptosis (caveolin 2), mRNA metab-
olism (5'-3' exoribonuclease 1), mitochondrial fatty acid
oxidation (acyl coenzyme A dehydrogenase), as well as
kinase and protease activities (TAU tubulin kinase 1 and
corin, respectively). Taken together, their diverse expres-
sion is most likely involved in determining tumor pheno-
type, i.e. associating higher proportions of the poorly
differentiated carcinomas or the highly differentiated pap-
illary adenocarcinomas with the expression of
STAT5Δ750 or STAT5ca, respectively [15].
Overall, 94% of the genes specifically affected by STAT5ca
were downregulated relative to their expression in the
host tissue. This contrasts with the more equal specific
effect of the STAT5Δ750 variant and provides additional
evidence for the distinct routes via which the two STAT5
variants impose their mark on tumor growth and mainte-
nance. The high number of tumor and growth suppressors
defined among the STAT5ca-downregulated genes vs. the
potent oncogenes (Met, Igf2) that were induced by the
STAT5Δ750 variant may serve to further distinguish the
routes via which they initiate and maintain tumorigene-
sis.
Substantial downregulation of gene expression has been
demonstrated in breast cancers with bone marrow (BM)
micrometastasis [58], and during the molecular transition
from organ-confined to metastatic prostate cancer [59].
Apparently, transcription repression is important for the
metastatic process in these tissues. When compared with
the list of genes downregulated by STAT5ca-, no overlap
was observed for those associated with BM micrometasta-
sis, and only four genes (Ptn, Cflar, Cnn1 and Mpdz)
shared the list of downregulated genes mediating prostate
metastasis. Thus, the resultant tumor characteristics are
probably determined by a combination of the phenome-
non of gene downregulation per se and the properties of
the specifically affected genes (in this case by STAT5ca).
Our attempt to characterize the different roles of the
STAT5 variants in mammary cancer development did not
produce any evidence for the effect of transgenic STAT5
expression in the tumors. Neither distinct metabolic path-
ways nor a central mediator(s) were located. This suggests
domination of an earlier STAT5 effect on the resulting
gene-expression profiles. Several groups of genes, each
composed of three to eight members, with significant
internal correlations were identified among the sets spe-
cifically affected by STAT5ca and STAT5Δ750. This corre-
lation was not associated with physical linkage. Within a
single group, genes with correlated expression might con-
trol a distinct range of cellular functions such as angiogen-
esis (Ptn and Tyrp1 [60,61]), apoptosis (Cflar, [62]) and
morphogenesis (Ebf2, [63]). Their comparable levels of
expression, defined by their location in a confined region
within the cluster, suggest that although these genes are
mapped to several loci, they may colocalize to a shared
transcription site. The concept of several loci being tar-
geted to a shared transcription site where they generate
"transcription factories" with similar levels of expression
was proposed a few years ago and is reviewed in [64,65].
The relevance of this biological system to the specific
STAT5 effects presented in this study remains to be deter-
mined. Regardless of the detailed mechanism involved in
the effect of STAT5Δ750 and STAT5ca on tumor growth
and maintenance, this study establishes the feasibility of
identifying and distinguishing mammary tumors accord-
ing the variants' signature on specific gene-expression pro-
files. To the best of our knowledge, this signature is
specific to the effect of the STAT5 variants. However, its
uniqueness will only be confirmed by the contribution of
further gene-expression profiles that are specific for the
effects of other oncogenes.
Conclusion
The C-terminally truncated form of Stat5 and its constitu-
tively active variant retain oncogenic potency that is con-
veyed via distinct pathways and probably initiated during
early stages of tumor development. The detailed results of
this study may have clinical implications regarding the
decision of whether, and when, to use putative anti-Stat5
therapy [66].
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